company background image
CELZ

Creative Medical Technology Holdings NasdaqCM:CELZ Stock Report

Last Price

US$0.73

Market Cap

US$10.2m

7D

-1.9%

1Y

-94.4%

Updated

17 Aug, 2022

Data

Company Financials +
CELZ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CELZ Stock Overview

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments.

Creative Medical Technology Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Creative Medical Technology Holdings
Historical stock prices
Current Share PriceUS$0.73
52 Week HighUS$17.15
52 Week LowUS$0.58
Beta4.73
1 Month Change-0.57%
3 Month Change-52.56%
1 Year Change-94.35%
3 Year Change-99.19%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Shareholder Returns

CELZUS BiotechsUS Market
7D-1.9%1.8%4.5%
1Y-94.4%-22.2%-8.9%

Return vs Industry: CELZ underperformed the US Biotechs industry which returned -22.2% over the past year.

Return vs Market: CELZ underperformed the US Market which returned -8.9% over the past year.

Price Volatility

Is CELZ's price volatile compared to industry and market?
CELZ volatility
CELZ Average Weekly Movement13.5%
Biotechs Industry Average Movement12.5%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: CELZ is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: CELZ's weekly volatility has decreased from 25% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a4Tim Warbingtonhttps://www.creativemedicaltechnology.com

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Creative Medical Technology Holdings Fundamentals Summary

How do Creative Medical Technology Holdings's earnings and revenue compare to its market cap?
CELZ fundamental statistics
Market CapUS$10.21m
Earnings (TTM)-US$8.67m
Revenue (TTM)US$92.75k

110.1x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CELZ income statement (TTM)
RevenueUS$92.75k
Cost of RevenueUS$50.24k
Gross ProfitUS$42.51k
Other ExpensesUS$8.71m
Earnings-US$8.67m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.62
Gross Margin45.84%
Net Profit Margin-9,342.00%
Debt/Equity Ratio0.06%

How did CELZ perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CELZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CELZ?

Other financial metrics that can be useful for relative valuation.

CELZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does CELZ's PB Ratio compare to its peers?

CELZ PB Ratio vs Peers
The above table shows the PB ratio for CELZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.6x
BRTX BioRestorative Therapies
0.6xn/aUS$10.9m
ACOR Acorda Therapeutics
0.1xn/aUS$11.5m
TENX Tenax Therapeutics
1.1x-32.4%US$7.2m
SPRC SciSparc
0.8xn/aUS$6.3m
CELZ Creative Medical Technology Holdings
0.4x10.3%US$10.3m

Price-To-Book vs Peers: CELZ is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (0.6x).


Price to Earnings Ratio vs Industry

How does CELZ's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: CELZ is good value based on its Price-To-Book Ratio (0.4x) compared to the US Biotechs industry average (2x)


Price to Book Ratio vs Fair Ratio

What is CELZ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CELZ PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CELZ's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of CELZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CELZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CELZ's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Creative Medical Technology Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CELZ is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CELZ is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CELZ is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CELZ's revenue (105.3% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: CELZ's revenue (105.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CELZ's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Creative Medical Technology Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-3.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CELZ is currently unprofitable.

Growing Profit Margin: CELZ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CELZ is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.

Accelerating Growth: Unable to compare CELZ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CELZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: CELZ has a negative Return on Equity (-37.6%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Creative Medical Technology Holdings's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CELZ's short term assets ($22.9M) exceed its short term liabilities ($389.8K).

Long Term Liabilities: CELZ has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CELZ has more cash than its total debt.

Reducing Debt: CELZ had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CELZ has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CELZ has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 28% each year.


Discover healthy companies

Dividend

What is Creative Medical Technology Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CELZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CELZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CELZ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CELZ's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CELZ has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.5yrs

Average management tenure


CEO

Tim Warbington (60 yo)

6.5yrs

Tenure

US$98,680

Compensation

Mr. Timothy Warbington, also known as Tim, has served as the Director and as Chief Executive Officer of Creative Medical Technology Holdings, Inc. since February 2016 and serves as its President since May...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD98.68K) is below average for companies of similar size in the US market ($USD753.27K).

Compensation vs Earnings: Insufficient data to compare Tim's compensation with company performance.


Leadership Team

Experienced Management: CELZ's management team is seasoned and experienced (6.5 years average tenure).


Board Members

Experienced Board: CELZ's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CELZ insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 473.8%.


Top Shareholders

Company Information

Creative Medical Technology Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Creative Medical Technology Holdings, Inc.
  • Ticker: CELZ
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$10.212m
  • Shares outstanding: 14.07m
  • Website: https://www.creativemedicaltechnology.com

Number of Employees


Location

  • Creative Medical Technology Holdings, Inc.
  • 211 East Osborn Road
  • Phoenix
  • Arizona
  • 85012
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/17 00:00
End of Day Share Price2022/08/17 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.